Inhibition of the Rho/MRTF/SRF Pathway as a New Treatment for Systemic Sclerosis
Inhibition of the Rho/MRTF/SRF Pathway as a New Treatment for Systemic Sclerosis
批准号:
8671854
负责人:
Scott D Larsen
金额:
$65.55万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-05-01 至 2017-04-30
关键词:
ActinsAddressAdverse effectsAnimal ModelAnti-Inflammatory AgentsAnti-inflammatoryAreaBindingBleomycinCell NucleusCessation of lifeChemicalsCollagenConnective Tissue DiseasesCyclophosphamideDermalDevelopmentDiagnosisDiseaseDrug KineticsEtiologyExtracellular MatrixF-ActinFibroblastsFibrosisG ActinGastrointestinal tract structureGenesGenetic TranscriptionHealthHeartHumanImmune systemImmunosuppressive AgentsInflammatoryKidneyLeadLiver MicrosomesLuciferasesLungMaximum Tolerated DoseMediatingMedicalMetabolicMetabolismMethotrexateModelingMusMyofibroblastOrganOutcomePathologyPathway interactionsPatientsPermeabilityPositioning AttributePreventionProcessProductionPropertyResearchSclerodermaSeriesSerum Response ElementSerum Response FactorSignal PathwaySiteSkinSmooth Muscle Actin Staining MethodSolubilityStimulusSystemic SclerodermaTestingTissuesUp-RegulationVascular SystemWorkWound Healinganalogaqueouscytotoxicdesigneffective therapyextracellularimprovedin vitro Assayin vitro activityin vivoin vivo Modelinhibitor/antagonistinnovationlipophilicitymouse modelmyocardinnovelnovel therapeutic interventionphysical propertypreventpromoterrhosmall moleculetranscription factortreatment strategy
中文摘要
描述(由申请人提供):系统性硬化症(scleroderma, SSc)是一种结缔组织的破坏性纤维化疾病,目前尚无令人满意的治疗方案。它是一种多系统疾病,可导致皮肤和内脏器官纤维化,包括肺、心脏、肾脏和胃肠道。仅在美国就有10万至15万人患有SSc,每年约有1500例新病例被诊断出来。目前对SSc的管理需要使用免疫抑制剂,如甲氨蝶呤和环磷酰胺,这些药物具有细胞毒性且疗效有限。虽然SSc的病理和进展已被很好地描述,但其病因尚不清楚。SSc和其他纤维化的标志是正常成纤维细胞向肌成纤维细胞的转变,其特征是α-平滑肌肌动蛋白(α-SMA)的表达和富含胶原的细胞外基质(ECM)的产生。这种促纤维化成纤维细胞到肌成纤维细胞的传递素可被许多细胞外刺激诱导,其中大多数似乎依赖于RhoA信号通路。该途径导致g -肌动蛋白结合的心肌素相关转录因子(MRTF)的释放,随后MRTF在细胞核中积累,MRTF与血清反应因子(SRF)在血清反应元件(SRE)启动子上结合,随后导致一些促纤维化基因的表达上调,包括编码α-SMA的基因ACTA2。我们已经发现并开发了一类新的Rho/MRTF/SRF基因转录途径的小分子抑制剂。该系列的先导化合物(CCG-203971)可抑制TGF-β刺激的正常真皮成纤维细胞和SSc患者皮肤肌成纤维细胞中α-SMA的表达。尽管CCG-203971具有良好的体外活性,但其效力有限,药代动力学(PK)特性较差,限制了其在体内纤维化模型中用作研究抑制Rho/MRTF/SRF通路作用的探针。本研究的主要假设是,药物抑制Rho/MRTF/ srf介导的基因转录将是一种有效的治疗SSc的新策略。我们的方法将是:1)优化CCG-203971先导物的效价和预测良好PK的理化性质;2)评估体内PK的最佳新类似物;3)在两种互补的小鼠纤维化模型中评估最佳探针的疗效。该方案的创新之处在于,它将尝试通过破坏Rho/MRTF/SRF信号通路来治疗或预防纤维化,该通路位于多种细胞外促纤维化刺激的下游和共同的点。这项工作意义重大,因为它将首次尝试直接阻止导致纤维化的基本肌原纤维细胞分化。最后,这项工作的最终影响将是开发一种全新的治疗SSc和潜在的许多其他纤维化疾病的方法。
英文摘要
DESCRIPTION (provided by applicant): Systemic sclerosis (scleroderma, SSc) is a devastating fibrotic disease of the connective tissues, for which there are no satisfactory treatment options. It is a multisystem disorder that can cause fibrosis of the skin and internal organs, including lungs, heart, kidneys and the gastrointestinal tract. SSc afflicts 100,000-150,000 people in the US alone, with approximately 1500 new cases diagnosed each year. Current management of SSc entails the use of immunosuppressives such as methotrexate and cyclophosphamide, which are cytotoxic and of limited efficacy. Although the pathology and progression of SSc have been well described, the etiology of the disease is still not clear. The hallmark of SSc and other fibroses is the transition of normal fibroblasts into myofibroblasts, which are characterized by expression of alpha- smooth muscle actin (α-SMA) and production of collagen-rich extracellular matrix (ECM). This pro-fibrotic fibroblast-to-myofibroblast transitin can be induced by a number of extracellular stimuli, most of which appear to depend on the RhoA signaling pathway. This pathway leads to the release of G-actin-bound myocardin- related transcription factor (MRTF), subsequent accumulation of MRTF in the nucleus, binding of MRTF to serum response factor (SRF) on the serum response element (SRE) promoter, and consequent upregulation of expression of a number of pro-fibrotic genes, including ACTA2, the gene encoding for α-SMA. We have discovered and developed a novel class of small molecule inhibitors of the Rho/MRTF/SRF gene transcription pathway. A lead compound from this series (CCG-203971) inhibits expression of α-SMA in both TGF-β-stimulated normal dermal fibroblasts as well as skin myofibroblasts from SSc patients. Despite this promising in vitro activity, CCG-203971 has modest potency and poor pharmacokinetic (PK) properties that limit its use as a probe for studying the effects of inhibiting the Rho/MRTF/SRF pathway in in vivo models of fibrosis. The overarching hypothesis of this proposal is that pharmacological inhibition of Rho/MRTF/SRF-mediated gene transcription will be an effective new treatment strategy for SSc. Our approach will be to: 1) optimize the lead CCG-203971 for both potency and physicochemical properties predictive of good PK; 2) evaluate the best new analogs for in vivo PK; and 3) evaluate optimal probes for efficacy in two complementary mouse models of fibrosis. This proposal is innovative in that it will attempt to treat or prevent fibrosis through disruptionof the Rho/MRTF/SRF signaling pathway at a point that is downstream of and common to multiple extracellular pro-fibrotic stimuli. This work is significant in that it will attempt for the first ime to directly prevent the fundamental myofibrblast differentiation that underlies fibrosis. Finally, the ultimate impact of this work will be progress toward the development of an entirely new therapy for SSc and potentially many other fibrotic diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Probes for Studying Treatment of CNS-based Lysosomal Storage Diseases
-
批准号:8622088
-
项目类别:
-
资助金额:$60.79万
-
财政年份:2013
-
负责人:Scott D Larsen
-
依托单位:
Novel Probes for Studying Treatment of CNS-based Lysosomal Storage Diseases
-
批准号:8481819
-
项目类别:
-
资助金额:$64.18万
-
财政年份:2013
-
负责人:Scott D Larsen
-
依托单位:
Novel Probes for Studying Treatment of CNS-based Lysosomal Storage Diseases
-
批准号:8827388
-
项目类别:
-
资助金额:$58.99万
-
财政年份:2013
-
负责人:Scott D Larsen
-
依托单位:
Design of CNS-Permeable Agents for the Treatment of Lipid Storage Diseases
-
批准号:7934607
-
项目类别:
-
资助金额:$22.75万
-
财政年份:2009
-
负责人:Scott D Larsen
-
依托单位:
海外基金